Erleada (apalutamide) can interact with other medications and certain foods. For example, it can interact with atorvastatin (Lipitor) and grapefruit. Erleada is a prescription oral tablet used to ...

NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide) in patients with hormone-relapsed or hormone sensitive disease in first draft guidance. The cost-effectiveness ...

Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of ...

Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA ® reduced risk of death by 23 percent at 24 months compared to enzalutamide LISBON, Portugal, Oct. 2, 2024 /PRNewswire/ -- ...

Johnson & Johnson JNJ is one of the key pharmaceutical players in the oncology segment with significant expertise in blood cancers and solid tumors. It is the #1 company in multiple myeloma, with key ...

Johnson & Johnson is counting on Erleada to carry the prostate cancer baton as Zytiga battles generics. And it just got one step closer to a new indication. Wednesday, the New Jersey drugmaker said ...

Johnson & Johnson's Janssen is offering an additional tablet strength of Erleada (apalutamide). The introduction of a 240 mg tablet provides the first-and-only option for a once-daily, single-tablet ...

Erleada shows consistent 24-month overall survival in real-world settings and the TITAN trial for metastatic castration-sensitive prostate cancer. Erleada reduces the risk of death by 23% compared to ...

The extension is based on data from the Phase III TITAN study, which assessed the addition of the drug to androgen deprivation therapy in a broad range of patients with metastatic hormone-sensitive ...

BARCELONA—Johnson & Johnson may not have technically shown yet that Erleada can extend the lives of patients with nonmetastatic castration-resistant prostate cancer. But the company still thinks its ...

Prostate cancer therapy now recommended for two indications within its marketing authorisation The UK’s National Institute of Health and Care Excellence (NICE) has recommended Janssen’s Erleada ...

RARITAN, N.J., May 26, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the ...